 |
 |

Carvedilol, Metoprolol, and Insulin Resistance
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: The study by Dr Bakris and colleagues1 comparing the metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension found that insulin sensitivity improved with carvedilol (9.1%; P = .004) but not metoprolol (2.0%; P = .48), with a between-group difference of 7.2% (95% confidence interval [CI], 13.8% to 0.2%). The reference the article cites supporting the use of the Homeostasis Model AssessmentInsulin Resistance (HOMA-IR) as the tool to measure insulin resistance was the study by Haffner et al.2 This was a prospective study assessing predictors of development of diabetes mellitus in 3.5 years of follow-up. Jayagopal et al3 studied the variation of HOMA indices and showed that to consider a change of HOMA as clinically significant, the new value must represent at least a 90% increase or a 47% decrease. The mean improvement in HOMA-IR of 9% in the present study may . . . [Full Text of this Article]
Edgard Gonzalez-Feldman, MD
egonzal2@hfhs.org Endocrinology Division Henry Ford Hospital Detroit, Mich
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLES
Carvedilol, Metoprolol, and Insulin ResistanceReply
David S. Bell and George L. Bakris
JAMA. 2005;293(10):1190.
EXTRACT
| FULL TEXT
Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial
George L. Bakris, Vivian Fonseca, Richard E. Katholi, Janet B. McGill, Franz H. Messerli, Robert A. Phillips, Philip Raskin, Jackson T. Wright, Jr, Rosemary Oakes, Mary Ann Lukas, Karen M. Anderson, David S. H. Bell, and for the GEMINI Investigators
JAMA. 2004;292(18):2227-2236.
ABSTRACT
| FULL TEXT
|